{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:53Z","timestamp":1782337253286,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics LLP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:54:47Z","timestamp":1744372487000},"page":"739-745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-1510","authenticated-orcid":false,"given":"Chaitra","family":"Ujjani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Broome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-2755","authenticated-orcid":false,"given":"Edus H","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1851-3938","authenticated-orcid":false,"given":"Nicole","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton","family":"Grossfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-7655","authenticated-orcid":false,"given":"Bruce D","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.clml.2025.04.004_bib0001","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.04.004_bib0002","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-Human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.clml.2025.04.004_bib0003","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2025.04.004_bib0004","first-page":"3080","article-title":"Drug screening reveals that Ibrutinib (PCI-32765) exhibits synergy with BCL-2 and proteasome inhibitors in models of mantle cell lymphoma and CLL","volume":"122","author":"Brett","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.04.004_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024","volume":"22","author":"Wierda","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.clml.2025.04.004_bib0006","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.clml.2025.04.004_bib0007","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-16-0555","article-title":"Combination of Ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma","volume":"16","author":"Kuo","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"27","key":"10.1016\/j.clml.2025.04.004_bib0008","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initialevaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.004_bib0009","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1182\/blood-2023-174914","article-title":"Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed\/refractory indolent non-hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.004_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration Ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clml.2025.04.004_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.3163_49","article-title":"High efficacy and favorable safety of 3rd generation cd20 car-t (mb-106) for outpatient treatment of follicular lymphoma \u2014Results of a single-institution trial","volume":"41","author":"Shadman","year":"2023","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.04.004_bib0012","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:07:41Z","timestamp":1758604061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025001284"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}